Literature DB >> 19243073

Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.

Susie M D Henley1, Edward J Wild, Nicola Z Hobbs, Chris Frost, David G MacManus, Roger A Barker, Nick C Fox, Sarah J Tabrizi.   

Abstract

Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD. (c) 2009 Movement Disorder Society.

Entities:  

Mesh：

Year:  2009        PMID： 19243073     DOI： 10.1002/mds.22485

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  20 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

2.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

3.  The structural correlates of functional deficits in early huntington's disease.

Authors:  Christine Delmaire; Eve M Dumas; Michael A Sharman; Simon J A van den Bogaard; Romain Valabregue; Céline Jauffret; Damian Justo; Ralf Reilmann; Julie C Stout; David Craufurd; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Stéphane Lehéricy
Journal:  Hum Brain Mapp       Date:  2012-03-22       Impact factor: 5.038

4.  Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.

Authors:  Charlotte Soneson; Magnus Fontes; Yongxia Zhou; Vladimir Denisov; Jane S Paulsen; Deniz Kirik; Asa Petersén
Journal:  Neurobiol Dis       Date:  2010-08-02       Impact factor: 5.996

5.  Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.

Authors:  Rachael I Scahill; Nicola Z Hobbs; Miranda J Say; Natalie Bechtel; Susie M D Henley; Harpreet Hyare; Douglas R Langbehn; Rebecca Jones; Blair R Leavitt; Raymund A C Roos; Alexandra Durr; Hans Johnson; Stéphane Lehéricy; David Craufurd; Christopher Kennard; Stephen L Hicks; Julie C Stout; Ralf Reilmann; Sarah J Tabrizi
Journal:  Hum Brain Mapp       Date:  2011-11-18       Impact factor: 5.038

6.  Longitudinal change in regional brain volumes in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Peggy C Nopoulos; Christopher A Ross; Douglas R Langbehn; Ronald K Pierson; James A Mills; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Jane S Paulsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-30       Impact factor: 10.154

Review 7.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

8.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

9.  Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Authors:  Valerio Leoni; Jeffrey D Long; James A Mills; Stefano Di Donato; Jane S Paulsen
Journal:  Neurobiol Dis       Date:  2013-04-01       Impact factor: 5.996

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.